Efficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology group

Basit Öğe Kaydı
dc.contributor.authorErol, Cihan
dc.contributor.authorSendur, Mehmet Ali Nahit
dc.contributor.authorBilgetekin, Irem
dc.contributor.authorGarbioglu, Duygu Bayir
dc.contributor.authorHamdard, Jamshid
dc.contributor.authorAkbas, Sinem
dc.contributor.authorHizal, Mutlu
dc.date.accessioned2024-02-23T14:37:53Z
dc.date.available2024-02-23T14:37:53Z
dc.date.issued2022
dc.departmentNEÜen_US
dc.description.abstractAims: The addition of aflibercept to the fluorouracil and irinotecan (FOLFIRI) regimen significantly improved clinical outcomes in patients with metastatic colorectal cancer (CRC) previously treated with oxaliplatin. We aimed to investigate the efficacy and safety of second-line FOLFIRI and aflibercept combination in patients with metastatic CRC in real-life experience. Materials and Methods: Four hundred and thirty-three patients who treated with FOLFIRI and aflibercept in the second-line were included in the study. The clinical and pathological features of the patients were recorded retrospectively. Survival (overall and progression-free survival [PFS]), response rates, and safety data were analyzed. Results: The median age was 61. Majority of patients (87.5%) received first-line bevacizumab and 10.1% of patients received anti-epidermal growth factor receptor agents. About 80% of patients had KRAS, 18.6% of patients had NRAS, and 6.4% of patients had BRAF mutations. The median OS was 11.6 months (95% confidence interval [CI], 10.6-12.6) and the median PFS was 6 months (95% CI, 5.5-6.5). About 4.6% of patients had complete response and 30.6% of patients had partial response as best tumor response. Grade 1-2 toxicities were seen in 33.4% of patients, while grade 3-4 toxicities were recorded in 27% of patients. Eight patients (2%) died due to treatment toxicity. Conclusions: Overall and PFS were similar in routine clinical practice compared to phase III pivotal VELOUR trial. However, response rates were found to be higher. It was observed that there were fewer adverse events compared to the VELOUR trial.en_US
dc.identifier.doi10.4103/jcrt.jcrt_1104_21
dc.identifier.endpageS353en_US
dc.identifier.issn0973-1482
dc.identifier.issn1998-4138
dc.identifier.issue9en_US
dc.identifier.pmid36510987en_US
dc.identifier.scopus2-s2.0-85143994465en_US
dc.identifier.scopusqualityQ3en_US
dc.identifier.startpageS347en_US
dc.identifier.urihttps://doi.org/10.4103/jcrt.jcrt_1104_21
dc.identifier.urihttps://hdl.handle.net/20.500.12452/16250
dc.identifier.volume18en_US
dc.identifier.wosWOS:000908442000034en_US
dc.identifier.wosqualityQ4en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherWolters Kluwer Medknow Publicationsen_US
dc.relation.ispartofJournal Of Cancer Research And Therapeuticsen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectAflibercepten_US
dc.subjectClinical Practiceen_US
dc.subjectColorectal Canceren_US
dc.subjectReal-Life Dataen_US
dc.subjectSecond-Lineen_US
dc.titleEfficacy and safety of folfiri plus aflibercept in second-line treatment of metastatic colorectal cancer: Real-life data from Turkish oncology groupen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu